Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.83 |
| ▸ | NPC1 | O15118 | 1/20 | 0.83 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30292770 | 1.00 | RAB9A (0.83) | RAB9ANPC1NR2F2ALDH1A1SMN1; SMN2 | |
| SCHEMBL24072152 | 0.91 | RAB9A (0.81) | RAB9ANPC1NR2F2ALDH1A1SMN1; SMN2 | |
| SCHEMBL24072197 | 0.91 | RAB9A (1.00) | RAB9ANPC1NR2F2ALDH1A1SMN1; SMN2 | |
| SCHEMBL24072629 | 0.91 | RAB9A (1.00) | RAB9ANPC1NR2F2ALDH1A1SMN1; SMN2 | |
| SCHEMBL24072159 | 0.88 | RAB9A (0.90) | RAB9ANPC1NR2F2ALDH1A1SMN1; SMN2 | |
| SCHEMBL24072179 | 0.88 | RAB9A (0.94) | RAB9ANPC1NR2F2ALDH1A1SMN1; SMN2 | |
| SCHEMBL6791608 | 0.88 | CYP2C19 (0.76) | RAB9ANPC1NR2F2ALDH1A1SMN1; SMN2 | |
| SCHEMBL24072651 | 0.87 | RAB9A (0.78) | RAB9ANPC1NR2F2ALDH1A1SMN1; SMN2 | |
| SCHEMBL30292743 | 0.87 | RAB9A (0.78) | RAB9ANPC1NR2F2ALDH1A1SMN1; SMN2 | |
| SCHEMBL24072663 | 0.86 | RAB9A (0.75) | RAB9ANPC1NR2F2ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212122-A1 | MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-07-06 | — | — | US | disclosed |
| US-20230212122-A1 | MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-07-06 | — | — | US | disclosed |
| WO-2021242753-A1 | MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212122-A1 | MITOCHONDRIAL TARGETING COMPOUNDS FOR THE TREATMENT OF ASSOCIATED DISEASES | TFAM, CS, FH | RAB9A 839/4885NPC1 1157/4885NR2F2 2589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.